Adaptive Biotechnologies (ADPT) Cash & Equivalents (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash & Equivalents across 9 years of filings, most recently posting $77.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $77.6 million, up 53.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.6 million (up 53.18% YoY), and the FY2025 annual result was $70.5 million, up 47.11% from the prior year.
• Cash & Equivalents came in at $77.6 million for Q1 2026 at Adaptive Biotechnologies, up from $70.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $217.6 million in Q3 2022 to a low of $38.1 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $71.2 million (2024), against an average of $80.6 million.
• Across the five-year window, Cash & Equivalents soared 77.74% in 2022 and slumped 59.22% in 2023, its largest moves.
• Adaptive Biotechnologies' Cash & Equivalents stood at $90.0 million in 2022, then decreased by 27.73% to $65.1 million in 2023, then slipped by 26.35% to $47.9 million in 2024, then jumped by 47.11% to $70.5 million in 2025, then increased by 10.05% to $77.6 million in 2026.
• The last three Cash & Equivalents figures came in at $77.6 million (Q1 2026), $70.5 million (Q4 2025), and $55.0 million (Q3 2025), per Business Quant data.